The type 1 insulin-like growth factor receptor (IGF1R) and its ligands (IGF-I and IGF-II) have been implicated in a variety of physiologic processes and in diseases such as cancer. In addition to IGF1R, IGF-II also activates the insulin receptor (IR) isoform A, and therefore, antibodies against IGF-II can inhibit cell proliferation mediated by the signaling through both IGF1R and IR triggered by IGF-II. We identified a new human monoclonal antibody (mAb), m708.2, which is bound to IGF-I and IGF-II but not to insulin. m708.2 potently inhibited signal transduction mediated by the interaction of IGF-I or IGF-II with the IGF1R and IGF-II with the IR. It also inhibited the growth of the breast cancer cell line MCF-7. An affinity-matured derivative of m708.2, m708.5, bound to IGF-I with equilibrium dissociation constant, K D ¼ 200 pmol/L and to IGF-II with K D ¼ 60 pmol/L. m708.5 inhibited signal transduction mediated by IGF-I and IGF-II and cancer cell growth more potently than m708.2. These results suggest that m708.5 could have potential as a candidate therapeutic for cancers driven by the IGF-I and IGF-II interactions with IGF1R and IR. Mol Cancer Ther; 10(9); 1-9. Ó2011 AACR.
Introduction
The type 1 insulin-like growth factor receptor (IGF1R) and its ligands (IGF-I and IGF-II) have been implicated in a variety of physiologic processes and in pathologic conditions such as cancer (1) (2) (3) (4) . Although the role of the IGF system in cancer has been recognized many years ago, it is not until recent years that the system's components have been targeted and shown to affect cell transformation, proliferation, survival, motility, and migration in tissue cultures and in mouse models of cancers (5-7). The IGF1R shares a similar tetrameric a2b2 structure with insulin receptor (IR). The IGF-mediated signaling is initiated by the binding of IGF-I and IGF-II to their receptor IGF1R, which induces conformational changes in the transmembrane domain of the b subunit. The conformational changes further lead to transphosphorylation of the kinase domain in the 2 b chains (8) . The phosphorylated and fully activated IGF1R recruits adaptor proteins such as insulin receptor substrate (IRS) 1, IRS2, and Src-homology collagen (SHC; ref. 9) . The phosphorylation of IRS1 regulates the activity of phosphoinositide 3-kinase and protein kinase B (also known as Akt) and triggers the activation of some transcription factors that control the expression of many genes that are important for cell proliferation and growth (3) . Numerous studies show that IGF1R is expressed in a broad panel of tumors, suggesting that inhibition of IGF1R signaling may have both proapoptotic and antiproliferative consequences (10) . Thus, it seems that the modulation of the activity of the IGF system could add to the arsenal of anticancer therapeutic approaches (11) . Different strategies aimed at targeting the IGF system have been investigated including small molecule tyrosine kinase inhibitors, antisense technologies (12) , monoclonal antibodies (mAbs) targeting the IGF1R (10, 13, 14) , IGF-I (15), and IGF-II (11, 16) . They inhibit the kinase activity or disrupt the interaction of IGF1R with its ligands IGF-I and IGF-II, and downregulate the levels of IGF1R.
MAbs have been highly successful as cancer therapeutics. Great progress in clinical and preclinical stages has been made in developing antibodies aimed at targeting IGF system components (17) . During the past several years, a number of mAbs against the IGF1R have been identified with cancer cell growth inhibitory activity (10, 13, 18, 19) . However, the IGF1R is not very significantly overexpressed in tumors and the mAbs could bind to normal cells expressing the receptor with possible toxic effects. Antibodies against the ligands IGF-I and IGF-II that inhibit the interaction with IGF1R may not have these undesirable effects. Most anti-IGF1R antibodies do not inhibit IGF1R-IR hybrid receptor. IGF-II-mediated signaling through the hybrid receptor could escape the blockage by IGF1R antibodies. In addition, another consideration is that binding to the ligands, which is not cell associated but is diffusible, may not require significant penetration into solid tumors, thus avoiding problems associated with penetration (11) . A rat monoclonal antibody KM1468, which is cross-reactive to human IGF-I and IGF-II, could suppress the development of new bone tumors and the progression of established tumors (20, 21) . KM1468 inhibits tumor growth and increases survival in a mouse model of hepatic metastasis induced by human colorectal cancer cell line, HT29 (21) . More recently, several human mAbs against IGF-II have been reported (11, 16) and IGF-I and an IGF-II cross-reactive mAb is also described (22) . These results suggest that binding to IGF-I and IGF-II can markedly affect tumor growth and that mAbs against the 2 ligands are promising candidate therapeutics.
Here, we describe the identification and characterization of a human mAb (m708.5) which bound with high affinity to IGF-I (K D ¼ 200 pmol/L) and IGF-II (K D ¼ 60 pmol/L). It potently inhibited signal transduction mediated by the IGF1R interaction with IGF-I and IGF-II and the interaction of the IR with IGF-II, resulting in the inhibition of phosphorylation of IGF1R, IR, and cancer cell growth. These results suggest that m708.5 may have potential as a candidate therapeutic.
Materials and Methods

Panning of a large phage displayed Fab library
Recombinant human IGF-I was used to pan a human naive Fab phage library containing 10 10 unique clones as previously described (23) .
Mutagenesis by error-prone PCR
Error-prone PCR of the entire scFv gene was carried out using Stratagene GeneMorph II Random Mutagenesis Kit according to the instructions of the manufacturer. Briefly, PCR was done in a 50-mL reaction containing 1Â Mutazyme II reaction buffer, 0.5 mmol/L each of primers:
0 -deoxy-p-nucleoside-5 0 -triphosphate, and 2.5 U of Mutazyme II DNA polymerase. The reaction mixtures were denatured at 95 C for 2 minutes, cycled 35 times at 95 C for 1 minute, 60 C for 1 minute, and 72 C for 1 minute and finally extended at 72 C for 10 minutes. The PCR products were gel purified and amplified in 4 100-mL PCR reactions containing 1Â Accuprime PCR reaction mix (Invitrogen), 1 mmol/L of primers YDRDF (5 0 -CTTCGCTGTTTTTCAATATTTTCTGTTATTGCTTCAG-TTTTGGCCCAGGCGGCC-3 0 ) and YDRDR (5 0 -GAGCC-GCCACCCTCAGAACCGCCACCCTCAGAGCCACCA-CTAGTTGGGCCGGCCTG-3 0 ), 120 ng of error-prone PCR product, and 2.5 U of Accuprime pfx DNA polymerase (Invitrogen). The reactions were thermally cycled using the same conditions except that 30 cycles were used. Amplified insert was gel purified and concentrated using vacuum concentrator.
Construction of yeast displayed mutant libraries
The yeast display vector used for library construction, pYD7, was modified from pCTCON2 (24) . Two SfiI restriction sites of pYD7 before and after the scFv matched the cloning sites of the phage display vector. This allowed fragments to be conveniently shuttled between the yeast vector and phage display vector. Furthermore, to better present displayed antibodies on yeast surface, scFvs were fused at the N-terminal of the yeast protein agglutinin (Aga2p).
The pYD7 vector was digested with SfiI and gel purified. Multiple aliquots of 12 mg of mutagenized scFv DNA and 4 mg of plasmid DNA were concentrated into 20 to 30 mL of water. The pYD7-scFv libraries were then electroporated into competent yeast cells EBY100 prepared as described previously (25) . Briefly, 10 mL of EBY100 yeast cells in YPD media (10 g/L yeast nitrogen base, 20 g/L peptone, and 20 g/L glucose) were grown at 30 C with shaking at 250 rpm overnight. The culture was inoculated into 100 mL of fresh YPD and allowed to grow to OD 600 of 1.6 before collecting by centrifugation. The cell pellet was washed twice with 50 mL of cold water and once with 50 mL cold electroporation buffer The methodology for generating and isolating higher affinity mutants was as described in references (24, 26, 27) . Antigen concentrations are chosen based on the equilibrium dissociation constant (K D ) of the parental antibody. The antigen incubation volume must be large enough to allow at least 10-fold excess of the antigen over amounts of scFv displayed on yeast (assuming 5 Â 10 Two and 3 FACS selections were carried out in second and third round. Yeast cells were pelleted, washed in PBSA buffer, resuspended in PBSA buffer with biotinylated IGF-I (ranging from 3 to 0.1 nmol/L) and mouse anti-c-myc antibody, and incubated on ice. Cells were then washed with PBSA twice and resuspended in 1 mL PBSA with R-phycoerythrin-conjugated streptavidin and Alexa Fluor 488-conjugated goat anti-mouse antibody.
After the first and second round, yeast plasmids were isolated using Zymoprep Yeast Plasmid Miniprep II Kit (Zymo Research) according to the manufacturer's instructions and used as templates for error-prone PCR to amplify gene repertoire for the construction of the second and third mutant libraries. Cells from the last selection of the third round were spread on SDCAA plates. Monoclonal yeast cells were characterized, and isolated antibodies with improved affinity were sequenced.
Conversion to IgG1 and expression of Fab, scFv, and IgG1
We used the same procedure as previously described (29) . Fab and scFv were expressed and purified as previously described (30, 31) .
ELISA binding assay
Antigens (50 ng) per well were coated on 96-well ELISA plates overnight at 4 C. For phage ELISA, approximately 1 Â 10 10 plaque-forming unit phages were incubated with antigen for 1 hour. Bound phages were detected with anti-M13-HRP mAb (1:3,000; GE Healthcare). For Fab and IgG1 ELISA, Fabs and IgG1s with different dilutions were incubated with antigens for 1 hour. Bound Fabs were detected with anti-FLAG-HRP mAb (1:3,000; Sigma). Bound IgG1s were detected with anti-human Fc-HRP mAb (1:2,000; Invitrogen). The 2,2 0 -azino-bis-(3-ethylbenzthiazoline-6-sulfonic acid) substrate (Sigma) was added and the reaction was read at 450 nm.
Affinity measurement of yeast-displayed scFvs
The equilibrium dissociation constant was determined essentially as previously described (32) .
Affinity determination by surface plasmon resonance
Interactions between various isolated antibodies and IGF-I and IGF-II were analyzed by surface plasmon resonance technology using a Biacore X100 instrument (GE healthcare). IGF-I or IGF-II was covalently immobilized onto a sensor chip (CM5) using carbodiimide coupling chemistry. A control reference surface was prepared for nonspecific binding and refractive index changes. For analysis of the kinetics of interactions, varying concentrations of antibodies were injected at flow rate of 30 mL/min using running buffer containing 10 mmol/L HEPES, 150 mmol/L NaCl, 3 mmol/L EDTA, and 0.05% Surfactant P-20 (pH ¼ 7.4). The association and dissociation phase data were fitted simultaneously to a 1:1 model by using BIAevaluation 3.2. All the experiments were done at 25 C.
Competition assay scFv or IgG1 m708.5 (10 nmol/L) was incubated with 5 nmol/L biotinylated human IGF-I and 1 nmol/L biotinylated human IGF-II at room temperature for 20 minutes. The mixtures were added to 5 Â 10 5 MCF-7 cells in 50 mL PBSA buffer and incubated for 30 minutes on ice. After washing once, cells were incubated with a 1:50 dilution of R-phycoerythrin-conjugated streptavidin for 30 minutes on ice, then washed again, and resuspended in 0.5 mL PBSA buffer. Analysis was conducted using a BD Bioscience FACScalibur. Irrelevant anti-gp41 MPER scFv-3A2a (unpublished data) and anti-Nipah/Hendra viruses IgG1-m102.4 (33) were used as negative controls.
Phosphorylation assay
Measurement of IGF1R and IR phosphorylation was conducted as previously described (11) except that the treatment medium was made by adding 1 nmol/L human IGF-I or 5 nmol/L human IGF-II.
Cell growth assay
Cell growth and inhibition were measured as previously described (11) except that IGF-I (2.5 nmol/L) was also used in addition to IGF-II (2.5 nmol/L).
Results
Identification of a high affinity IGF-I and IGF-II cross-reactive human mAb, m708.2
To develop human mAbs against human IGF-I, we used a large size ($10 10 independent clones) naive human Fab phage-displayed library. A recombinant human IGF-I was conjugated to magnetic beads and used as the antigen for pannings. After 3 rounds of panning, more than 200 random individual phage clones were screened by phage ELISA against IGF-I. Clones that exhibited significant binding to IGF-I were sequenced. Finally, 3 clones with unique sequences were found. They were expressed in bacteria as soluble Fabs, purified, and tested for binding activity in ELISA. Two Fabs, designated m705 and m706, showed binding specifically to IGF-I only, whereas 1 Fab, m708, bound to both IGF-I and IGF-II in ELISA (Supplementary Fig. S1 ). m708 was selected for affinity maturation by light chain shuffling.
Two rounds of panning of the light chain shuffled library (containing 2 Â 10 8 independent clones) against IGF-I-conjugated magnetic beads were conducted, and 200 clones from the second round of panning were screened by phage ELISA. Among them, Fab m708.2 showed markedly higher binding to both IGF-I and IGF-II than the parental m708 version (data not shown) and was selected for further improvement.
Construction of m708.2 mutant libraries displayed on yeast and selection of a picomolar affinity binder, m708.5
To further increase the affinity of m708.2, it was converted to a scFv and randomly mutagenized by errorprone PCR. We used yeast display for further maturation, because it allows fine discrimination between mutants by flow cytometry and our attempts to increase affinity by phage display were not successful. Therefore, the mutant library was displayed on yeast cells by homologous recombination with a vector containing a C-terminal Aga2 protein and c-myc tag. To obtain large amounts of DNA insert and avoid improper incorporation at the site of homologous recombination, purified DNA obtained from the first PCR reaction was reamplified in a second PCR reaction. Thus, 30% to 40% of the transformed cells displayed scFvs as verified by flow cytometry (data not shown).
Mutant yeast library of relatively large (up to 10 9 ) size was generated and subjected first to 1 round of selection by using IGF-I-conjugated magnetic beads according to the method described in references (34, 35) . This allowed elimination of yeast cells that did not express antibodies or bound weakly to IGF-I. The library was then sorted several times by FACS for binding to IGF-I. The sorted scFvs were mutated by error-prone PCR of the entire gene to yield a new sublibrary. The process of sorting and mutagenesis was then cyclically repeated (Fig. 1) . The highest affinity clones from the final round of maturation were identified (Fig. 2) and their sequences were analyzed.
One dominant clone, m708.5, was identified by sequence analysis. Compared with m708.2, m708.5 had 2 amino acid substitutions in the heavy chain CDR2 (H2), 2 amino acid substitutions in H3, and 9 amino acid substitutions in the framework region (Table 1 ). There were 4 substitutions in the framework regions of the light chain. These substitutions resulted in a remarkable improvement of affinity but still retaining cross-reactivity as measured by 2 different methods. The first method was based on yeast-displayed scFvs that were incubated with varying concentrations of biotinylated IGF-I or IGF-II. The affinity of yeast-displayed m708.5 scFv for IGF-I was increased 39-fold compared with that of m708.2 (1 Â 10 À10 vs. 3.9 Â 10 À9 mol/L), whereas its affinity for IGF-II was increased 27-fold (4.1 Â 10 À11 vs. 1.1 Â 10 À9 mol/L; Table 2 ). Similar values were obtained for isolated soluble scFv m708.5 as measured with surface plasmon resonance ( Supplementary  Fig. S2 ): 2 Â 10 À10 mol/L for IGF-I and 6.1 Â 10 À11 mol/L for IGF-II, compared with scFv m708.2 (2.2 Â 10 À9 mol/L for IGF-I and 1.8 Â 10 À9 mol/L for IGF-II; Table 2 ). Therefore, the cross-reactive antibody m708.2 was successfully matured to a scFv, m708.5, with picomolar affinity for both IGF-I and IGF-II.
Avidity of IgG1 m708.5
The scFv m708.5 was converted to an IgG1 format and its avidity measured with surface plasmon resonance. IgG1 m708.5 showed increased binding for both IGF-I and IGF-II compared with scFv m708.5. The effective K D of m708.5 for IGF-I and IGF-II was 1,000-fold and 60-fold higher than K D for scFv, respectively (data not shown). The measured K D (<10 À12 mol/L) is below the sensitivity of the Biacore instrument [10 6 (mol/L) À1 s À1 for k on and 10 À6 s À1 for k off ] and therefore may not be reliable. IgG1 m708.5 was also much more effective in binding to both IGF-I and IGF-II than m708.2 as measured by ELISA (Fig. 3) . Thus, m708.5 exhibited very high avidity in IgG1 format, resulting in much stronger binding than in scFv format. IGFs bind and activate IGF1R and the signals transduced by this pathway lead to cell proliferation. To find whether m708.5 inhibits binding of IGF-I and IGF-II to IGF1R and IR, we used the breast cancer cell line MCF-7, which has been shown to express both receptors. m708.5 in scFv and IgG1 completely blocked IGF-I and IGF-II binding to their receptors on MCF-7 cells (Fig. 4) . Control scFv and IgG that did not recognize IGFs had no effect. The antibody also inhibited IGF-I-induced (1 nmol/L) or IGF-II-induced (5 nmol/L) phosphorylation. Immunoblottings (Fig. 5A) showed that from 1 to 100 nmol/L, m708.5 completely inhibited the IGF-I-induced phosphorylation of IGF1R. Similar inhibitory activity was also observed with m708.2, which however only partly blocked IGF-I-induced phosphorylation at 10 nmol/L. In addition to IGF-I, both m708.2 and m708.5, as well as m610 were capable of inhibiting IGF-II-induced phosphorylation of IGF1R (Fig. 5B) . However, m708.5 was superior to m708.2 ( Fig. 5B) and competed with m610. The antibodies also inhibited IGF-II-mediated phosphorylation of the IR induced by 5 nmol/L of IGF-II (Fig. 5C) . The inhibition was independent on human insulin that m708.5 did not bind (Fig. 5D) . Therefore, m708.5 could effectively inhibit ligand-induced phosphorylation of the 2 receptors without inhibiting insulin-IR interaction.
Inhibition of MCF-7 cell growth by m708.5
To investigate whether the blocking of IGF binding by m708.5 is potent enough to inhibit the proliferation of cells, we tested the activity of m708.5 in a cell growth assay using MCF-7 cells. After 3 days of treatment, the cell growth was almost completely inhibited at 320 nmol/L of m708.5 ( Fig. 6) . At concentrations higher than 40 nmol/L, m708.5 treatment resulted in more than 40% cell growth inhibition. In contrast, m708.2 could only inhibit cancer cells at concentrations higher than 80 nmol/L and 40% inhibition was achieved above 160 nmol/L. It is noteworthy that MCF-7 cells produced significant amounts of IGF-II concentrations of up to 35 nmol/L after 3 days (11) . These data showed that the potency of m708.5 was remarkably improved compared with m708.2, and it effectively inhibited tumor cell proliferation in vitro.
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Discussion
The IGF signaling system plays an important role in tumorigenesis (36) . Human IGF-I and IGF-II share 62% sequence identity and have overlapping functions: both IGF-I and IGF-II can activate the IGF1R that can drive tumor cell proliferation. A remarkable feature of IGF-II (but not IGF-I) is that it can also bind to the IR and enhance cell proliferation. To further explore novel cancer therapeutics based on human mAbs targeting components of the IGF system, we identified 3 human antibodies specific for IGF-I using phage display technologies. One of them, m708, exhibited also significant binding to human IGF-II and was further affinity matured by light chain shuffling, mutagenesis, and yeast display. The affinity-maturated antibody, m708.5, potently inhibited both IGF-I-and IGF-II-induced phosphorylation of IGF1R as well as IGF-II-induced phosphorylation of the IR and less potently growth of MCF-7 cancer cell-expressing IGF1R.
The inhibitory activity of the antibodies was cell type dependent (data not shown) with a likely major determinant being the surface concentration of the IGF1R and the IR. To date, many IGF1R-specific antibodies have been under preclinical studies and several are being evaluated in clinical trials (1) . We previously reported a human mAb (m610) with high affinity to IGF-II that potently blocked the growth/migration of human cancer lines in vitro (11) and significantly suppressed the growth of prostate cancer cells in a human bone environment (37) . A murine mAb cross-reactive to human IGF-I and IGF-II inhibited the development of new bone tumors and the progression of established tumors (20) . Recently, a new mAb against IGF-I and IGF-II was reported that was effective in a mouse model of caner with cells expressing high levels of IGF1R (22) . On the basis of the data described in our article and those previously reported, we believe that m708.5 would also exhibit inhibitory activity in vivo. The finding that IgG1 m708.5 also binds IGF-I and IGF-II is important, because it would allow the use of the IgG antibody format, which is most stable and has long half-life in vivo. m708.5 is a fully human mAb cross-reactive to both human IGF-I and IGF-II with picomolar affinity and potently inhibits signal transduction mediated by IGF-I and IGF-II interacting with IGF1R and IGF-II interacting with IR. It also inhibits potently tumor cell growth in vitro and is likely to exert similar activity in vivo. Importantly, m708.5 cross-reacts to mouse IGF-I and IGF-II (Supplementary Fig. S3 ). Therefore, the activity of m708.5 can be tested with human xenografts in mouse models of cancer where it could inhibit both autocrine (human) and paracrine (mouse) IGF. Therefore, m708.5 offers a new and promising therapeutic strategy for treating tumor cells and a possible therapeutic addition to IGF1R-targeted agents. It could be used in combination with other IGF-I and IGF-II-or IGF1R-targeting mAbs and also with other cancer therapeutics. We do not know where exactly its epitope is located, although it inhibits binding of IGF-I and IGF-II to both IGF1R and IR, and therefore, its epitope may overlap with their binding sites although steric hindrance is also possible. It competes with our previously identified anti-IGF-II mAb m610 for binding to IGF-II, and therefore, their epitopes are likely to be overlapped although steric hindrance could not be excluded. It would be interesting to find out whether m708.5 competes with the recently described mAbs against IGF-I and IGF-II. Further research is needed to exactly localize the epitope of m708.5 and evaluate its inhibitory properties in vivo as a candidate therapeutic.
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